A genome-wide association study of kynurenic acid in cerebrospinal fluid: Implications for psychosis and cognitive impairment in bipolar disorder

Molecular Psychiatry

Volumn 21, Issue 10, 2016, Pages 1342-1350

  Sellgren, C M ^a   Kegel, M E ^a   Bergen, S E ^a   Ekman, C J ^a   Olsson, S ^a   Larsson, M ^a   Vawter, M P ^b   Backlund, L ^a,c   Sullivan, P F ^d   Sklar, P ^e   Smoller, J W ^f,g   Magnusson, P K E ^a   Hultman, C M ^a   Walther Jallow, L ^c   Svensson, C I ^a   Lichtenstein, P ^a   Schalling, M ^a,c   Engberg, G ^a   Erhardt, S ^a   Landen M ^a,h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; INTERLEUKIN 1BETA; KYNURENIC ACID; SORTING NEXIN;

ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN TISSUE; CEREBROSPINAL FLUID LEVEL; CHROMOSOME 1P; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EXECUTIVE FUNCTION; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; SNX7 GENE; AGED; BRAIN; CEREBROSPINAL FLUID; CHROMOSOME 1; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIPOLAR DISORDER; BRAIN; CHROMOSOMES, HUMAN, PAIR 1; COGNITION DISORDERS; COGNITIVE DYSFUNCTION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KYNURENIC ACID; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SORTING NEXINS;

EID: 84949843575     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.186     Document Type: Article

References (49)

1. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-98.
2. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530.
3. Olsson SK, Samuelsson M, Saetre P, Lindstrom L, Jonsson EG, Nordin C et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010; 35: 195-199.
4. Olsson SK, Larsson MK, Erhardt S. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm 2012; 119: 155-163.
5. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-432.
6. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophe-notypes. Arch Gen Psychiatry 2011; 68: 665-674.
7. Lavebratt C, Olsson S, Backlund L, Frisen L, Sellgren C, Priebe L et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry 2014; 19: 334-341.
8. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477.
9. Soderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118.
10. Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009; 14: 1069-1071.
11. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
12. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
13. Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep 2000; 2: 286-290.
14. Olsson SK, Sellgren C, Engberg G, Landen M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord 2012; 14: 719-726.
15. Alexander KS, Wu HQ, Schwarcz R, Bruno JP. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 2012; 220: 627-637.
16. Perianez JA, Rios-Lago M, Rodriguez-Sanchez JM, Adrover-Roig D, Sanchez-Cubillo I, Crespo-Facorro B et al. Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: sample comparisons and normative data. Arch Clin Neuropsychol 2007; 22: 433-447.
17. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE et al. The International Society for Bipolar Disorders-Battery for Assessment of Neuro-cognition (ISBD-BANC). Bipolar Disord 2010; 12: 351-363.
18. Bora E, Yucel M, Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study. J Affect Disord 2010; 127: 1-9.
19. Szatmari P, Maziade M, Zwaigenbaum L, Merette C, Roy MA, Joober R et al. Informative phenotypes for genetic studies of psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 581-588.
20. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373: 234-239.
21. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984-994.
22. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
23. Homack S, Lee D, Riccio CA. Test review: Delis-Kaplan executive function system. J Clin Exp Neuropsychol 2005; 27: 599-609.
24. Bergen SE, O'Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S et al. Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry 2012; 17: 880-886.
25. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011; 478: 519-523.
26. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22: 437-442.
27. Hoshi T, Yamagami H, Furukado S, Miwa K, Tanaka M, Sakaguchi M et al. Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors. Eur J Neurol 2010; 17: 1134-1140.
28. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 2002; 175: 45-53.
29. Hayes AF, Preacher KJ. Statistical mediation analysis with a multicategorical independent variable. Br J Math Stat Psychol 2013; 67: 451-470.
30. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 2011; 7: e1002003.
31. Lai F, Orom UA, Cesaroni M, Beringer M, Taatjes DJ, Blobel GA et al. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 2013; 494: 497-501.
32. Teasdale RD, Collins BM. Insights into the PX (phox-homology) domain and SNX (sorting nexin) protein families: structures, functions and roles in disease. Biochem J 2012; 441: 39-59.
33. Xu L, Yin W, Xia J, Peng M, Li S, Lin S et al. An antiapoptotic role of sorting nexin 7 is required for liver development in zebrafish. Hepatology 2012; 55: 1985-1993.
34. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011; 472: 319-324.
35. Dupaul-Chicoine J, Saleh M. A new path to IL-1beta production controlled by caspase-8. Nat Immunol 2012; 13: 211-212.
36. Urata Y, Koga K, Hirota Y, Akiyama I, Izumi G, Takamura M et al. IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am J Reprod Immunol 2014; 72: 496-503.
37. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-1074: 25-37.
38. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806.
39. Erhardt S, Oberg H, Mathe JM, Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 2001; 20: 353-362.
40. Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 2009; 12: 501-512.
41. Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med 2008; 38: 771-785.
42. Ibrahim HM, Tamminga CA. Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol 2012; 13: 1587-1594.
43. Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psycho-pharmacology 2008; 200: 217-230.
44. Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 2011; 61: 262-267.
45. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science 2013; 339: 156-161.
46. Sloan SA, Barres BA. Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders. Curr Opin Neurobiol 2014; 27: 75-81.
47. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477: 54-60.
48. Solovieff N, Milton JN, Hartley SW, Sherva R, Sebastiani P, Dworkis DA et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010; 115: 1815-1822.
49. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014; 46: 543-550.